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Abstract
Background: Experimental studies support the anti-neoplastic effect of apo(a), but several clinical studies have reported
contradictory results. The purpose of this study was to determine whether a low lipoprotein(a) [Lp(a)] concentration is
related to mortality from major causes of death, especially cancer.
Methods: The subjects were 10,413 participants (4,005 men and 6,408 women) from a multi-center population-based
cohort study in Japan (The Jichi Medical School cohort study). The average age at registration was 55.0 years, and the
median observation period was 4,559 days. As the estimated hazard ratio was high for both the low and very high Lp(a)
levels, we defined two Lp(a) groups: a low Lp(a) group [Lp(a),80 mg/L] and an intermediate-to-high Lp(a) group
[Lp(a)$80]. Participants who died from malignant neoplasms (n=316), cardiovascular disease (202), or other causes (312)
during the observation period were examined.
Results: Cumulative incidence plots showed higher cumulative death rates for the low Lp(a) group than for the
intermediate-to-high Lp(a) group for all-cause, cancer, and miscellaneous-cause deaths (p,0.001, p=0.03, and p=0.03,
respectively). Cox proportional hazards analyses with the sex and age of the participants, body mass index, and smoking
and drinking histories as covariates showed that a low Lp(a) level was a significant risk for all-cause, cancer, and
miscellaneous-cause deaths (p,0.001, p=0.003, and p=0.01, respectively). The hazard ratio (95% CI) [1.48, 1.15–1.92] of a
low Lp(a) level for cancer deaths was almost the same as that for a male sex (1.46, 1.00–2.13).
Conclusions: This is the first report to describe the association between a low Lp(a) level and all-cause or cancer death,
supporting the anti-neoplastic effect of Lp(a). Further epidemiological studies are needed to confirm the present results.
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Introduction
Large-scale prospective cohort studies and their meta-analyses,
including our study, have shown that hyperlipoproteinemia(a) is a
risk factor for coronary artery disease and stroke [1–4]. To reduce
the risk of hyperlipoproteinemia(a), the development of Lp(a)-
lowering therapies has been pursued, including lipid apheresis and
the use of antisense oligonucleotide [5–7].
Meanwhile, apolipoprotein(a) [apo(a)] is a unique protein found
only in old-world primates, including human beings and
hedgehogs. Despite the established association between Lp(a)
and cardiovascular disease, the physiological function and the
metabolism of apo(a) and the association of apo(a) with other
diseases remain unknown. The apo(a) gene (LPA) and the
plasminogen gene share a number of characteristic repeated
domains called Kringle. Angiostatin, a degraded product of
plasminogen, exerts an anti-neoplastic effect by inhibiting
angiogenesis [8]. A phase II study on angiostatin has been
performed in patients with non-small cell lung cancer [9]. As LPA
also has Kringle structures, apo(a) may also have an anti-neoplastic
effect [10]. A recombinant protein (LK68) of LPA Kringle type IV
and V experimentally suppressed tumor growth and capillary
density within tumors in mice [11]. Gene therapy inducing an
LK68 recombinant gene suppressed the tumor growth of
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e31954transplanted hepatocellular carcinoma in mice [12] and liver
metastasis and peritoneal dissemination in a murine colon cancer
model [13,14]. Tumor growth and angiogenesis were also
suppressed in apo(a)-transgenic mice [15]. An 11-amino acid
short peptide deduced from LPA Kringle type V also had an
anti-neoplastic effect [16]. All these experimental studies support
the anti-neoplastic effect of apo(a), but several clinical studies
have reported contradictory results, with the serum Lp(a) level
being elevated in cancer-bearing patients or not being signifi-
cantly different from that of the control group [17–25]. These
clinical studies, however, had several limitations. The number of
cancer cases was generally small, and some studies lacked data
regarding the histological type or the clinical stage of the cancer
or the presence or absence of metastasis to the liver, which
produces Lp(a). No prospective studies regarding the association
between Lp(a) and cancer have been reported to date.
To test the hypothesis that a low Lp(a) concentration is related
to cancer deaths, we analyzed data from the Jichi Medical School
(JMS) cohort study, a large-scale, multi-center, population-based
cohort study conducted in Japan. To our surprise, a low Lp(a)
concentration was associated not only with cancer deaths, but also
with all-cause and miscellaneous-cause deaths. The implications of
these interesting results are also discussed in this article.
Methods
Ethics Statement
The Jichi Medical University ethics committee approved the
study, and each subject provided their written informed consent.
The JMS Cohort Study
The JMS cohort study was comprised of 12 population-based
cohorts from the Tohoku to Kyusyu regions in Japan; the study
was started in 1992 to clarify the risk factors for cardiovascular and
cerebrovascular diseases among the Japanese population. Local
residents attending regular medical checkups based on a legal
mass-screening system were asked to participate in the JMS cohort
study [26]. A total of 12,490 residents were registered between
1992 and 1995. These residents included 95 participants who did
not consent to the follow-up studies and 2 participants who moved
away prior to the baseline study. All the participants were Japanese
according to the information obtained from their residence
certificates. In 10,692 of the participants (85.6%), the serum
Lp(a) level was measured at the time of the baseline examination
using an ELISA kit (Biopool, Uppsala, Sweden; interassay CV,
3.5) [27,28]. The lowest detection limit was 10 mg/L, and the
undetectable level was considered to be 5 mg/L for the statistical
analysis. The main reason for the relatively high percentage
(14.4%) of Lp(a)-unmeasured subjects was the lack of an Lp(a)
measurement kit in some areas. There were no meaningful
differences between the Lp(a)-unmeasured and the Lp(a)-measured
subjects. A survival analysis showed no significant difference
between the two groups (p=0.66). The subjects of this study were
generally healthy and consisted of 10,413 participants, excluding
279 participants with a history of stroke, myocardial infarction, or
malignant neoplasm at the time of the baseline examination.
The first quartile, median, and third quartile of the observation
period were 4,201 days, 4,559 days, and 4,900 days, respectively.
More than 90% of the participants were followed for more than
3,837 days.
Habits, medical history, and diagnostic criteria
The habits and medical history of each participant were
obtained using a questionnaire administered at the time of the
baseline examination [26]. The smoking history covered both past
and current smoking habits. If a participant consumed alcohol
more than three times a week, he or she was considered to be a
habitual drinker. The drinking history covered both past and
current drinking habits. The diagnostic criteria for myocardial
infarction defined in the World Health Organization’s MONICA
project and the diagnostic criteria for stroke defined by the
Yanagawa group for stroke research of the Japanese Ministry of
Health and Welfare were adopted.
Death of the participants
Overall, 830 participants died during the observation period;
the cause of death was obtained from each participant’s death
certificate. The participants died from malignant neoplasms
(316 participants), cerebrovascular disease (97), heart disease
(92), miscellaneous vascular disease (13), other diseases or causes
(311), and an unknown cause (1). The primary sites of the
malignant neoplasms were as follows: lung (59), stomach (28),
colon (19), liver (18), biliary tree (23), pancreas (21), hematopoietic
organs (21), and other organs (127).
Statistical analysis
To assess the hypothesis that a low Lp(a) concentration is related
to cancer deaths, we first examined the possible non-linear relation
between the Lp(a) level and the survival time, such as the hazard
ratio for the low Lp(a) concentration non-parametrically assessed
using restricted cubic splines [29]. We used the likelihood ratio test
for non-linearity, comparing the model only with the linear term
and that with the linear and cubic spline terms. Setting the Lp(a)
threshold at 80 mg/L seemed reasonable, considering the U-
shaped curve of the estimated hazard ratio versus the Lp(a) level
shown in Figure 1. Based on the results of this analysis and
considering the hazard ratio and the number of cases in each
group, we defined the two Lp(a) groups as follows: a low Lp(a)
group [Lp(a),80 mg/L (25th percentile); n=2,537], and an
intermediate-to-high Lp(a) group [Lp(a)$80 mg/L; n=7,876].
The Fisher exact test or Mann-Whitney test was used to assess the
statistical significance of differences in categorical variables or
continuous variables, respectively, between the groups. For each
group, cumulative incidence curves were used in a competing-risk
setting to calculate the probability of cardiovascular, cancer, and
Figure 1. Estimated hazard ratio of death against lipopro-
tein(a) level. Note a U-shaped curve of the estimated hazard ratio,
especially the significant increase in the hazard ratio for lipoprotein(a)
levels below 80 mg/L. The reference value for lipoprotein(a) was set at
270 mg/L.
doi:10.1371/journal.pone.0031954.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e31954miscellaneous-cause mortality for two Lp(a) groups, since we
confirmed that the type-specific hazard functions were not the
same for all event types (Figures S1 and S2). The Gray test was
used for group comparisons of cumulative incidence [30]. The
overall survival was calculated using the Kaplan-Meier method,
and the log-rank test was used for group comparisons of overall
survival. The association of Lp(a) with the outcomes was evaluated
using multivariate analyses, the use of a multivariate Cox
proportional-hazards regression to adjust for other outcomes,
and the use of the Fine and Gray proportional hazards model for
the subdistribution of a competing risk for other outcomes [31]. All
the models were adjusted for age, sex, body mass index, and
smoking and habitual drinking histories. To confirm the feasibility
of this two grouping in cause-specific deaths, we performed a Cox
proportional hazard analysis of the serum lipoprotein(a) levels
divided into quartiles. Setting the Lp(a) threshold at 80 mg/L
seemed to be reasonable for cause-specific deaths (Table S1). The
power of the analysis was calculated based on a log-rank test to
detect a hazard ratio of 1.4 for the endpoint between the low Lp(a)
group and the intermediate-to-high Lp(a) group at a two-sided
overall significance level of 5%. Allowing for a loss-to-follow-up
rate of less than 1% for all groups, a 98.5% power was estimated
for a 12.5-year follow-up.
All the p values were two-sided, and a p value less than 0.05 was
considered significant. The statistical analysis was performed using
the SAS system for Windows (ver. 9.1.3; SAS Institute Inc, Cary,
NC, USA). The cause-specific cumulative death rate was
calculated using R2.13.1.
Results
Serum Lp(a) level
The Lp(a) level ranged from 5 mg/L to 2,150 mg/L and
showed a highly skewed distribution toward the lower levels. The
25th, 50th, and 75th percentiles were 80, 150, and 270 mg/L,
respectively. The log-transformed Lp(a) values followed a normal
distribution (p,0.05).
As mentioned in the Methods section, we assessed the non-
linear relation between the Lp(a) level and the survival time.
Figure 1 shows a U-shaped curve for the estimated hazard ratio
against the Lp(a) level; the hazard ratio gradually decreased with
the Lp(a) level from 0 to 270 mg/L and sharply increased
thereafter. The shape of the curves did not depend on gender, and
the Lp(a) thresholds for both genders were the same as that for all
the participants.
Table 1 summarizes the baseline data of the subjects according
to two Lp(a) groups. The low Lp(a) group was characterized by a
male predominance; a younger age at registration; more frequent
smoking and alcohol drinking habits; a larger height, weight, and
body mass index; a higher total cholesterol level; and a lower
triglyceride level.
Figure 2. Cumulative death rates for all-cause and cause-specific deaths among two lipoprotein(a) [Lp(a)] groups. The cumulative
death rates of the low Lp(a) group were significantly higher than those of the intermediate-to-high Lp(a) group for all-cause, cancer, and
miscellaneous-cause deaths.
doi:10.1371/journal.pone.0031954.g002
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The survival analysis showed higher cumulative death rates for
the low Lp(a) group than for the intermediate-to-high Lp(a) group
for all-cause death, cancer death, and miscellaneous-cause death,
as shown in Figure 2. The subjects were divided into three Lp(a)
groups: a low Lp(a) group [Lp(a),80 mg/L (25th percentile);
n=2,537], an intermediate Lp(a) group [80#Lp(a),550 mg/L
(95th percentile); n=7,332], and a very high Lp(a) group
[Lp(a)$550 mg/L; n=544]. The cumulative death rate of the
very high Lp(a) group was not higher than that of the intermediate
Lp(a) for all-cause or any cause-specific deaths (Figure S3).
Additionally, we estimated the survival curves of the primary-
site-specific cancer deaths (Figure S4). In the low Lp(a) group, the
cumulative death rates were significantly higher for liver cancer
death (n=18). The cumulative death rates were not significantly
different between the low and intermediate-to-high Lp(a) groups
for deaths caused by digestive system cancers excluding liver
cancer (n=104), lung cancer (n=59), and other cancers (n=135).
Cox proportional hazards analysis
Table 2 shows the results of the proportional hazards analysis. A
low Lp(a) level was a significant risk factor for all-cause deaths
(p,0.001), cancer deaths (p=0.003), and miscellaneous-cause
deaths (p=0.01). The hazard ratio (95% CI), 1.48 (1.15–1.92), for
a low Lp(a) level for cancer deaths was almost the same as that
(1.46, 1.00–2.13) for a male sex. A gender-specific analysis showed
no significant differences in all-cause deaths or specific-cause
deaths between genders (Table S2). We also estimated the risk of a
low Lp(a) level for each primary site of malignancy (Table S3). A
low Lp(a) level was a significant risk factor for liver cancer and
cancers of the digestive system. The hazard ratio was very high
(5.23; 95%CI, 2.01–13.6) for death from liver cancer. A low Lp(a)
level was not a significant risk factor for death from lung cancer or
other cancers. To exclude the possibility of reverse causation, 20
subjects with liver cirrhosis (n=2) or liver cancer (n=18) were
excluded from the subjects. A subsequent Cox proportional hazard
analysis showed similar results: the hazard ratio (95% CI) of a low
Lp(a) level for death from cancer was 1.35 (1.03–1.77), p=0.03. If
the 91 subjects who died within two years after registration were
excluded from the subjects, similar results were obtained: the
hazard ratio for all-cause death was 1.43 (95%CI, 1.21–1.70;
p,0.0001). When the subjects were divided into three Lp(a)
groups, a very high Lp(a) level was not a risk factor for all-cause or
any cause-specific deaths (Table S4).
Discussion
The present study showed that a low Lp(a) level was a risk factor
for all-cause, cancer, and miscellaneous-cause deaths. This is the
first report describing the clinical and epidemiological significance
of a low Lp(a) concentration. Since no definition of a low Lp(a)
concentration, otherwise described as hypolipoproteinemia(a),
exists, we defined an Lp(a) level of less than 80 mg/L as a low
Lp(a) concentration in the present study. Further validation studies
are necessary to determine the threshold of hypolipoproteinemia(a)
in other populations.
Lp(a) and all-cause/cardiovascular deaths
Although hyperlipoproteinemia(a) is an established risk factor
for the onset of atherosclerotic disease, especially coronary artery
disease and stroke [1–4], only a few reports have discussed the
associations between hyperlipoproteinemia(a) and all-cause or
cardiovascular deaths [32–34]. A meta-analysis of several long-
term prospective studies of Caucasian subjects revealed that
hyperlipoproteinemia(a) is a risk factor for coronary deaths, but
not for cancer deaths or nonvascular deaths other than cancer
[33]. The Chin-Shan Study showed that hyperlipoproteinemia(a)
was a risk for all-cause deaths in a univariate analysis, but not in a
multivariate analysis [34]. The present study showed that both a
low and a very high Lp(a) level are risk factors for all-cause deaths.
However, no cohort studies regarding hypolipoproteinemia(a)
have been published to date.
Lp(a) and longevity
Several reports regarding the association between Lp(a) and
longevity have been made. Considering the cardiovascular risk
associated with hyperlipoproteinemia(a), very elderly subjects were
initially expected to have a low Lp(a) level. However, several
studies have repeatedly reported the presence of high Lp(a) levels
among centenarians [35–37]. These reports are consistent with
our result that a low Lp(a) level was a risk factor for all-cause
death.
Table 2. Cox proportional hazard analysis of low
lipoproteinemia(a) for all-cause and cause-specific deaths
(n=10,413).
Variables Hazard ratio (95% C.I.)p value*
All-cause deaths
Sex, men/women 1.56 (1.23–1.97) ,0.001
Age, per year 1.11 (1.10–1.11) ,0.001
Body mass index, per 1 kg/m
2 0.98 (0.95–1.00) 0.07
Smoking history, yes/no 1.64 (1.32–2.05) ,0.001
Alcohol history, yes/no 1.10 (0.92–1.31) 0.31
Lp(a), low/intermediate-to-high group
{ 1.43 (1.21–1.68) ,0.001
Cardiovascular deaths
Sex, men/women 1.21 (0.76–1.93) 0.41
Age, per year 1.13 (1.11–1.15) ,0.001
Body mass index, per 1 kg/m
2 1.03 (0.98–1.08) 0.27
Smoking history, yes/no 1.55 (1.00–2.41) 0.05
Alcohol history, yes/no 1.26 (0.88–1.80) 0.21
Lp(a), low/intermediate-to-high group
{ 1.31 (0.93–1.84) 0.12
Cancer deaths
Sex, men/women 1.46 (1.00–2.13) 0.05
Age, per year 1.09 (1.07–1.10) ,0.001
Body mass index, per 1 kg/m
2 1.00 (0.97–1.05) 0.83
Smoking history, yes/no 2.04 (1.43–2.92) ,0.001
Alcohol history, yes/no 1.01 (0.77–1.34) 0.92
Lp(a), low/intermediate-to-high group
{ 1.48 (1.15–1.92) 0.003
Miscellaneous-cause deaths
Sex, men/women 1.98 (1.34–2.91) ,0.001
Age, per year 1.11 (1.09–1.12) ,0.001
Body mass index, per 1 kg/m
2 0.91 (0.87–0.95) ,0.001
Smoking history, yes/no 1.36 (0.95–1.95) 0.09
Alcohol history, yes/no 1.08 (0.81–1.45) 0.60
Lp(a), low/intermediate-to-high group
{ 1.45 (1.10–1.90) 0.01
Abbreviations: C.I., confidence interval, Lp(a), lipoprotein(a).
*Statistically significant p values are shown in boldface.
{Low Lp(a) group, Lp(a),80 mg/L; intermediate-to-high Lp(a) group,
Lp(a)$80 mg/L.
doi:10.1371/journal.pone.0031954.t002
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because of the appearance of autoimmunity and chronic
inflammation of the upper respiratory and urinary tracts, and so
on, the levels of inflammatory markers, such as CRP, IL6, and
TNFa are likely to be elevated [35,38]. As Lp(a) is an acute-phase
reactant [39], the high Lp(a) level observed in centenarians might
be ascribed to age-associated chronic inflammation.
Lp(a) and cancer deaths
As an anti-neoplastic effect of apo(a) has been suggested, several
case-controlled studies have been conducted regarding the
association between the Lp(a) level and cancer. Patients with lung
or breast cancer exhibit elevated Lp(a) levels [17–20], while the
Lp(a) level was relatively low in patients with hepatocellular
carcinoma [21,22]. No significant differences in the Lp(a) level
were reported among patients with prostate cancer, ovarian
cancer, or acute lymphoblastic lymphoma [23–25]. The present
study showing the independent risk associated with a low Lp(a)
level for cancer deaths is compatible with previous experimental
studies.
A low Lp(a) level was correlated with higher cumulative death
rates from liver cancer in this study. Retrospective studies of
individuals who have received a hepatitis C virus-contaminated
blood transfusion have shown that liver cirrhosis and liver cancer
are likely to occur approximately 20 and 30–years after
transfusion, respectively [40]. About 90% of cases of liver cancer
in Japan are related to infection with hepatitis C or B virus [41].
Liver cirrhosis associated with liver cancer can lower the Lp(a)
level as a result of liver dysfunction. Thus, reverse causation may
explain some portion of the results; however, a low Lp(a) level was
still a risk for all-cause, cancer, or miscellaneous-cause deaths even
after the exclusion of subjects with liver cancer or liver cirrhosis or
the exclusion of subjects who died within two years of registration.
Overall, we assumed that the possibility of reverse causation was
not large.
Lp(a), miscellaneous-cause deaths, and inflammation
The association between a low Lp(a) level and miscellaneous-
cause deaths was an unexpected result. The most common cause
of miscellaneous-cause deaths was inflammatory disease, including
pneumonia. Limited information is available regarding the
association between the Lp(a) level and inflammation.
Lp(a) is an acute phase reactant [39]. The Lp(a) level increases
by approximately twice the baseline level and peaks at 11 days
after an acute myocardial infarction or at seven days after an
operation, then returns to the baseline level after one month [39].
Compared with other acute phase reactants, such as CRP, a1-acid
glycoprotein, a1-antitrypsin, or haptoglobin, the peak in the Lp(a)
level is delayed, suggesting that Lp(a) may play a role in reducing
inflammation or promoting tissue repair. As apo(a) is immunolo-
calized at small blood vessels in wounds [39,42], it may be related
to wound repair [43]. An experimental peritonitis model using
apo(a) transgenic mice showed that apo(a) suppressed the
inflammatory response by inhibiting neutrophil recruitment,
suggesting that apo(a) is a cell-specific suppressor of the
inflammatory response [44]. A clinical study of myocardial
infarction reported that hyperlipoproteinemia(a) was associated
with a decrease in coronary collateral circulation [45]. Thus, Lp(a)
may also suppress angiogenesis in cases with inflammation. All
these reports support the role of Lp(a) in tissue repair and the
suppression of excess inflammation through the inhibition of
angiogenesis or neutrophil recruitment. This anti-inflammatory
and wound-repairing effect of Lp(a) is in line with our results
regarding the significant association between a low Lp(a) level and
miscellaneous-cause deaths. In any case, little is known about the
relation between Lp(a) and inflammation, and future experimental
studies are required.
Limitations of this study
The contribution of Lp(a) to cardiovascular diseases differs
among races [46,47], but stratification was of minimal concern in
the present study because all the subjects were Japanese.
Although the analysis of the low Lp(a) concentration had a
sufficient statistical power, the relatively small number of deaths
(1,072 participants) among the subjects seemed to limit the
statistical power for detecting the hazard ratio of a very high
Lp(a) concentration or primary site-specific cancer deaths.
Since serum Lp(a) levels are not significantly affected by
external factors such as nutrition, smoking, drinking status, or
the use of drugs [48] and are known to remain unchanged during
long periods of life (12 years, or more than 20 years) [33, 49], we
assumed that the Lp(a) data measured at the baseline examination
would be representative of the Lp(a) throughout the study.
Conclusions
This is the first report of the epidemiological importance of a
low Lp(a) level for all-cause or cancer deaths. Further epidemi-
ological studies are warranted to confirm our results. The present
study seemed to support an anti-neoplastic effect of apo(a).
Supporting Information
Figure S1 Log-log survival plot for three causes of
death. The curves for cardiovascular deaths and miscellaneous-
cause deaths are much higher than that for cancer deaths when
the observation time is relatively short (early death); however, not
surprisingly, the curve for cancer deaths becomes higher than the
other two curves during later years. The close approximation of
the three curves during later years provides evidence against the
proportionality hypothesis.
(PPTX)
Figure S2 Smoothed hazards functions with Kernel
smoothing among three causes of death. The smoothed
hazard functions for miscellaneous-cause deaths and cardiovascu-
lar deaths are similar; however, this similarity is lost at eight to
nine years after registration. The sharp increase in the hazard for
miscellaneous-cause deaths after eight to nine years could arguably
be disregarded because the standard errors increase for later
observation times. As expected, the hazard for cancer deaths is
much higher than that for cardiovascular deaths, and gradually
increases with time.
(PPTX)
Figure S3 Cumulative death rates for all-cause and
cause-specific deaths among three lipoprotein(a) [Lp(a)]
groups. The cumulative death rates of the low Lp(a) group are
significantly higher than those of the intermediate Lp(a) group for
all-cause, cancer, and miscellaneous-cause deaths. The cumulative
death rate of the very high Lp(a) group is not higher than that of
the intermediate Lp(a).
(PPTX)
Figure S4 Cumulative death rates for primary site-
specific cancer deaths among two lipoprotein(a) [Lp(a)]
groups. The cumulative death rate of the low Lp(a) group
[Lp(a),80 mg/L] is significantly higher than that of the
intermediate-to-high Lp(a) group [Lp(a)$80 mg/L] in liver cancer
and noncancerous causes.
(PPTX)
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